Pioglitazone Lowers Systemic Asymmetric Dimethylarginine by Inducing Dimethylarginine Dimethylaminohydrolase in Rats

  title={Pioglitazone Lowers Systemic Asymmetric Dimethylarginine by Inducing Dimethylarginine Dimethylaminohydrolase in Rats},
  author={Shu Wakino and Koichi Hayashi and Satoru Tatematsu and Kazuhiro Hasegawa and Ichiro Takamatsu and Takeshi Kanda and Koichiro Homma and Kyoko Yoshioka and Naoki Sugano and Takao Saruta},
  journal={Hypertension Research},
Peroxisome proliferator activated receptor-γ (PPARγ) ligands increase nitric oxide (NO) production and reduce systemic blood pressure. Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOS) inhibitor degraded by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which has two isoforms, DDAH-I and -II. In order to elucidate the mechanism whereby PPARγ ligands affect NO metabolism, their effects on the DDAH-ADMA pathway were investigated. Six-week-old male Wister… 

Figures and Tables from this paper

Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.

Evidence of rapidly evolving evidence of isoform-specific distribution and regulation of DDAH expression in the kidney and blood vessels provides potential mechanisms for nephron site-specific regulation of NO production.

Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease

The current role of ADMA and D DAH in vascular health and disease, the techniques used to assess DDAH activity and expression, and the results of recent studies on pharmacological and biological agents modulating DDAh activity andexpression are discussed.

Asymmetric Dimethylarginine, an Endogenous NOS Inhibitor, Is Actively Metabolized in Rat Erythrocytes

This is the first report that the ADMA-metabolizing system, including the arginine methylation of proteins and the breakdown of free ADMA, occurs in circulating blood cell-populations, and that catalase in ECs might be a potential protein targeted by PRMT1.

Asymmetric Dimethylarginine Synthesis and Degradation Under Physiological and Pathological Conditions

In various pathological states such as hypercholesterolemia, hyperglycemia,hyperhomocysteinemia, hypertension, coronary artery disease, heart failure, and stroke, plasma levels of ADMA may increase twoor even tenfold, contributing to inhibition of NO synthesis and endothelial dysfunction.

cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases

Combined inhibition of PDE3 and 4 regresses development of pulmonary hypertension and promotes endothelial regeneration by modulating the ADMA-DDAH axis.

The clinical significance of asymmetric dimethylarginine.

Interestingly, next to its association with cardiovascular disease, ADMA also seems to play a role in other clinical conditions, such as critical illness, hepatic failure, and preeclampsia, and the field of research must be enlarged to elucidate the clinical significance of ADMA in these conditions.

Asymmetric dimethylarginine : assay methodology and serum levels in non-pregnant and pregnant women

It was found that the ADMA concentration varied during menstrual cycle and was dependent on hormonal status of women without oral contraceptive (OC) use, and ADMA, SDMA and L-arginine concentrations were elevated in normal pregnancy in comparison with the levels in non-pregnant females.

Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.

It is demonstrated that pioglitazone decreased serum ADMA levels in a glucose-lowering independent manner and may contribute to the reduction of serum levels of ADMA in IGT or T2DM subjects, thus playing a protective role against cardiovascular disease.

cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases

This work investigated whether combined phosphodiesterase (PDE) 3 and 4 inhibition ameliorates endothelial function by regulating the ADMA-DDAH axis by investigating the effects of the PDE3/4 inhibitor tolafentrine in vitro on endothelial cell survival, proliferation, and apoptosis.

Asymmetric Dimethylarginine (ADMA) and Endothelial Dysfunction: Implications for Atherogenesis

Several basic science and clinical research studies suggest that the increase in asymmetric dimethylarginine occurs in the context of chronic renal insufficiency, dyslipidemia, high blood pressure, diabetes mellitus, and hyperhomocysteinemy, as well as with other conditions.



Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension.

ADMA, independently of the renal dimethylargininase content, may play a role in the pathogenesis in Dahl salt-sensitive hypertensive rats but not in SHR, and the results suggest that the systemic production of ADMA is not dependent on renal dim methylargin inase.

Regulation of Cytokine-Induced Nitric Oxide Synthesis by Asymmetric Dimethylarginine: Role of Dimethylarginine Dimethylaminohydrolase

The results indicate two mechanisms of IL-1&bgr;–induced NO synthesis: the direct stimulation of the expression of iNOS and the indirect stimulation ofiNOS activity by upregulating DDAH and reducing ADMA.

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.

Elevation of ADMA is associated with impaired endothelium-dependent vasodilation and reduced urinary nitrate excretion and this abnormality is reversed by administration of L-arginine.

Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase

Compared the effects of intravenous low-dose ADMA and placebo on heart rate, blood pressure, cardiac output, and systemic vascular resistance at rest and during exercise, the hypothesis that ADMA is metabolized in humans in vivo by dimethylarginine dimethylaminohydrolase (DDAH) enzymes is tested.

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases.

The data suggest that the production of ADMA by human endothelial cells is regulated by S-adenosylmethionine-dependent methyltransferases, which may be due in part to the enhanced gene expression of PRMTs.

Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase

It is suggested that inhibition of dimethylarginine dimethylaminohydrolase increases the intracellular concentration of NG, NG‐dimethyl‐L‐argininine sufficiently to inhibit nitric oxide synthesis.

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension.

In male subjects with EH, endogenous systemic NO formation appears depressed, which is unrelated to accompanying insulin resistance or dyslipidemia, and circulating methylated analogs of L-arginine levels are increased in uncomplicated EH which may be of potential relevance.

Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits.

Elevation of the L-arginine/ADMA ratio may at least partly explain the restored NO formation by exogenous L- arginine in hypercholesterolemia.

Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?

Understanding of the pathophysiological role of asymmetric dimethylarginine could lead to novel therapies in the prevention of arteriosclerosis and coronary heart disease.

all-trans-Retinoic Acid Increases Nitric Oxide Synthesis by Endothelial Cells: A Role for the Induction of Dimethylarginine Dimethylaminohydrolase

It is demonstrated that atRA increases NO synthesis in endothelial cells without increasing eNOS expression and suggests that the induction of NO synthesis by atRA may be facilitated by DDAH II, which may help to explain some of the effects of atRA on the cardiovascular system.